Vitruvia Medical AG posted results in line with expectations in the first half of 2026. The Board of Directors confirms the full-year forecast.
Vitruvia Medical AG looks back on a successful first half of 2026 and remains fully on track with its business development. Particularly encouraging is the significant improvement in earnings: With CHF 125,785.97, the company was able to significantly increase its earnings compared to the same period last year (CHF -72,889.88), thereby impressively confirming the positive trajectory it has embarked upon.
Based on the company’s business performance in line with plans and the positive trend in the first half of the year, management confirms its positive outlook for the full year 2026 and believes the company remains well-positioned to achieve its targets.
LT technologies GmbH & Co. KG, a wholly owned subsidiary of Vitruvia Medical AG, looks back on a strong first half of 2026. The half-year revenue target of €1,300,000 was achieved as planned, putting the company on a stable course to meet its full-year target of €2.6 million